Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EC0905
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Oral, Intravenous, Intradermal, Subcutaneous, Intramuscular, Intraperitoneal, Intrathecal
01
Overview
EC0905 is a *folic acid–desacetylvinblastine hydrazide (DAVLBH) conjugate* designed as a targeted cytotoxic agent for cancer treatment. The drug connects folic acid to DAVLBH via a cleavable disulfide-containing hydrophobic linker. This configuration enables the compound to selectively bind to folate receptor-alpha (FRα)-positive cancer cells, leading to receptor-mediated endocytosis. Once internalized, the reducing environment within the endosome cleaves the linker, releasing DAVLBH, a potent microtubule inhibitor, to induce cytotoxicity. The conjugate’s design is intended to maximize anti-tumor efficacy while limiting toxicity to non-target cells. EC0905 is similar in design concept to vintafolide (EC145), a related folate-targeted vinca alkaloid conjugate.
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on EC0905.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EC0905.